Market Overview

Nanosphere Wins FDA Clearance to Market CYP2C19 Mutations Detection Test

Related NSPH
8 Biggest Mid-Day Winners
Mid-Morning Market Update: Markets Slightly Higher; Arbor Pharmaceuticals to Buy XenoPort For $7.03/Share

Nanosphere, Inc. (Nasdaq: NSPH) announced today the US FDA granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene^® System.

Posted-In: News FDA


Related Articles (NSPH)

View Comments and Join the Discussion!